{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T07:27:01Z","timestamp":1792394821669,"version":"4.4.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100009032","name":"Pfizer UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009032","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006484","name":"AbbVie Deutschland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006484","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13075-016-1170-3","type":"journal-article","created":{"date-parts":[[2016,11,24]],"date-time":"2016-11-24T01:16:25Z","timestamp":1479950185000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab"],"prefix":"10.1186","volume":"18","author":[{"given":"Gerd","family":"Horneff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Klotsche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Minden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Iko","family":"Huppertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Weller-Heinemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmin","family":"Kuemmerle-Deschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes-Peter","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Hospach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,24]]},"reference":[{"key":"1170_CR1","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390\u20132.","journal-title":"J Rheumatol"},{"key":"1170_CR2","first-page":"1377","volume":"33","author":"S Danner","year":"2006","unstructured":"Danner S, Sordet C, Terzic J, Donato L, Velten M, Fischbach M, et al. Epidemiology of juvenile idiopathic arthritis in Alsace, France. J Rheumatol. 2006;33:1377\u201381.","journal-title":"J Rheumatol"},{"key":"1170_CR3","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1056\/NEJM199204163261602","volume":"326","author":"EH Giannini","year":"1992","unstructured":"Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. the Pediatric Rheumatology Collaborative Study Group and The Cooperative Children\u2019s Study Group. N Engl J Med. 1992;326:1043\u20139. doi: 10.1056\/NEJM199204163261602 .","journal-title":"N Engl J Med"},{"key":"1170_CR4","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1055\/s-0031-1287837","volume":"223","author":"G Dueckers","year":"2011","unstructured":"Dueckers G, Guellac N, Arbogast M, Dannecker G, Foeldvari I, Frosch M, et al. Evidence and consensus based treatment guidelines 2010 for juvenile idiopathic arthritis by the German Society of Paediatric Rheumatology. Klin Padiatr. 2011;223:386\u201394. doi: 10.1055\/s-0031-1287837 .","journal-title":"Klin Padiatr"},{"key":"1170_CR5","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/acr.20460","volume":"63","author":"T Beukelman","year":"2011","unstructured":"Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. 2011;63:465\u201382. doi: 10.1002\/acr.20460 .","journal-title":"Arthritis Care Res"},{"key":"1170_CR6","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1056\/NEJM200003163421103","volume":"342","author":"DJ Lovell","year":"2000","unstructured":"Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000;342:763\u20139. doi: 10.1056\/NEJM200003163421103 .","journal-title":"N Engl J Med"},{"key":"1170_CR7","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/ard.2007.087411","volume":"68","author":"FH Prince","year":"2009","unstructured":"Prince FH, Twilt M, ten Cate R, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis. 2009;68:635\u201341.","journal-title":"Ann Rheum Dis"},{"key":"1170_CR8","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1136\/ard.2003.014886","volume":"63","author":"G Horneff","year":"2004","unstructured":"Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis. 2004;63:1638\u201344. doi: 10.1136\/ard.2003.014886 .","journal-title":"Ann Rheum Dis"},{"key":"1170_CR9","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1136\/ard.2007.087593","volume":"68","author":"G Horneff","year":"2009","unstructured":"Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis. 2009;68:519\u201325. doi: 10.1136\/ard.2007.087593 .","journal-title":"Ann Rheum Dis"},{"key":"1170_CR10","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1002\/art.27670","volume":"62","author":"N Ruperto","year":"2010","unstructured":"Ruperto N, Giannini EH, Pistorio A, Brunner HI, Martini A, Lovell DJ. Is it time to move to active comparator trials in juvenile idiopathic arthritis?: a review of current study designs. Arthritis Rheum. 2010;62:3131\u20139. doi: 10.1002\/art.27670 .","journal-title":"Arthritis Rheum"},{"key":"1170_CR11","doi-asserted-by":"crossref","unstructured":"Ramanan AV, Dick AD, McKay A, Jones A, Williamson P, Compeyrot-Lacassagne S, Hardwick B, Hickey H, Hughes D, Woo P, Benton D, Edelsten C, Beresford MW. A Randomised Controlled Trial of the Clinical Effectiveness, Safety and Cost-Effectiveness of Adalimumab in Combination with Methotrexate for the Treatment of Juvenile Idiopathic Arthritis Associated Uveitis [abstract].\u00a0Arthritis Rheumatol.\u00a02015; 67(suppl 10). http:\/\/acrabstracts.org\/abstract\/a-randomised-controlled-trial-of-the-clinical-effectiveness-safety-and-cost-effectiveness-of-adalimumab-in-combination-with-methotrexate-for-the-treatment-of-juvenile-idiopathic-arthritis-associated\/ .\u00a0","DOI":"10.1186\/1745-6215-15-14"},{"key":"1170_CR12","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1002\/art.38741","volume":"66","author":"H Schmeling","year":"2014","unstructured":"Schmeling H, Minden K, Foeldvari I, Ganser G, Hospach T, Horneff G. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry. Arthritis Rheumatol. 2014;66:2580\u20139. doi: 10.1002\/art.38741 .","journal-title":"Arthritis Rheumatol"},{"key":"1170_CR13","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1136\/annrheumdis-2014-205351","volume":"74","author":"HI Brunner","year":"2015","unstructured":"Brunner HI, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A, et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis. 2015;74:1110\u20137. doi: 10.1136\/annrheumdis-2014-205351 . annrheumdis-2014-205351.","journal-title":"Ann Rheum Dis"},{"key":"1170_CR14","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1517\/14656560903386300","volume":"10","author":"A Klein","year":"2009","unstructured":"Klein A, Horneff G. Treatment strategies for juvenile idiopathic arthritis. Expert Opin Pharmacother. 2009;10:3049\u201360. doi: 10.1517\/14656560903386300 .","journal-title":"Expert Opin Pharmacother"},{"key":"1170_CR15","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1136\/ard.2003.014886","volume":"63","author":"G Horneff","year":"2004","unstructured":"Horneff G, Schmeling H. Biedermann et al. The German Etanercept Registry for treatment of juvenile idiopathic arthritis (JIA). Ann Rheum Dis. 2004;63:1638\u201344.","journal-title":"Ann Rheum Dis"},{"key":"1170_CR16","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/art.24516","volume":"61","author":"A Consolaro","year":"2009","unstructured":"Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61:658\u201366. doi: 10.1002\/art.24516 .","journal-title":"Arthritis Rheum"},{"key":"1170_CR17","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","volume":"40","author":"EH Giannini","year":"1997","unstructured":"Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40:1202\u20139. doi: 10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R .","journal-title":"Arthritis Rheum"},{"key":"1170_CR18","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1002\/art.34373","volume":"64","author":"A Consolaro","year":"2012","unstructured":"Consolaro A, Bracciolini G, Ruperto N, Pistorio A, Magni-Manzoni S, Malattia C, et al. Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: defining criteria based on the juvenile arthritis disease activity score. Arthritis Rheum. 2012;64:2366\u201374. doi: 10.1002\/art.34373 .","journal-title":"Arthritis Rheum"},{"key":"1170_CR19","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1002\/art.1780371209","volume":"37","author":"G Singh","year":"1994","unstructured":"Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum. 1994;37:1761\u20139. doi: 10.1002\/art.1780371209 .","journal-title":"Arthritis Rheum"},{"key":"1170_CR20","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1136\/annrheumdis-2013-204641","volume":"74","author":"MH Otten","year":"2015","unstructured":"Otten MH, Anink J, Prince FH, Twilt M, Vastert SJ, Ten Cate R, et al. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register. Ann Rheum Dis. 2015;74:1379\u201386. doi: 10.1136\/annrheumdis-2013-204641 .","journal-title":"Ann Rheum Dis"},{"key":"1170_CR21","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa0706290","volume":"359","author":"DJ Lovell","year":"2008","unstructured":"Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359:810\u201320. doi: 10.1056\/NEJMoa0706290 .","journal-title":"N Engl J Med"},{"key":"1170_CR22","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/rheumatology\/keq361","volume":"50","author":"G Horneff","year":"2011","unstructured":"Horneff G, Foeldvari I, Minden K, Moebius D, Hospach T. Report on malignancies in the German juvenile idiopathic arthritis registry. Rheumatology (Oxford). 2011;50:230\u20136.","journal-title":"Rheumatology (Oxford)"},{"key":"1170_CR23","doi-asserted-by":"crossref","unstructured":"Horneff G, Klein A, Oommen PT, Hospach A, Foeldvari I, Feddersen I, Minden K. \u200bUpdate on malignancies in children with juvenile idiopathic arthritis in the German BIKER Registry.Clin Exp Rheumatol. 2016 Sep 8. [Epub ahead of print]","DOI":"10.1136\/annrheumdis-2016-eular.2755"},{"key":"1170_CR24","doi-asserted-by":"publisher","first-page":"278","DOI":"10.4081\/reumatismo.2013.682","volume":"65","author":"M Romano","year":"2013","unstructured":"Romano M, Pontikaki I, Gattinara M, Ardoino I, Donati C, Boracchi P, et al. Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients. Reumatismo. 2013;65:278\u201385. doi: 10.4081\/reumatismo.2013.682 .","journal-title":"Reumatismo"},{"key":"1170_CR25","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1002\/art.39197","volume":"67","author":"R Davies","year":"2015","unstructured":"Davies R, Southwood TR, Kearsley-Fleet L, Lunt M, Hyrich KL, British Society for Paediatric, Adolescent Rheumatology Etanercept Cohort Study. Medically significant infections are increased in patients with juvenile idiopathic arthritis treated with etanercept: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Arthritis Rheumatol. 2015;67:2487\u201394. doi: 10.1002\/art.39197 .","journal-title":"Arthritis Rheumatol"},{"key":"1170_CR26","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.3899\/jrheum.140472","volume":"42","author":"D Barthel","year":"2015","unstructured":"Barthel D, Ganser G, Kuester RM, Onken N, Minden K, Girschick HJ, et al. Inflammatory bowel disease in juvenile idiopathic arthritis patients treated with biologics. J Rheumatol. 2015;42:2160\u20135. doi: 10.3899\/jrheum.140472 .","journal-title":"J Rheumatol"},{"key":"1170_CR27","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","volume":"121","author":"WJ Sandborn","year":"2001","unstructured":"Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, et al. Etanercept for active Crohn\u2019s disease: a randomised, double-blind, placebo-controlled trial. Gastroenterology. 2001;121:1088\u201394.","journal-title":"Gastroenterology"},{"key":"1170_CR28","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/acr.22613","volume":"67","author":"I Foeldvari","year":"2015","unstructured":"Foeldvari I, Becker I, Horneff G. Uveitis events during Adalimumab, Etanercept, and methotrexate therapy in juvenile idiopathic arthritis: data from the biologics in Pediatric Rheumatology Registry. Arthritis Care Res (Hoboken). 2015;67:1529\u201335.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1170_CR29","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1093\/rheumatology\/ket170","volume":"52","author":"J Anink","year":"2013","unstructured":"Anink J, Otten MH, Gorter SL, Prince FHM, van Rossum MAJ, van den Berg JM, et al. Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab? Rheumatology (Oxford). 2013;52:1674\u20139. doi: 10.1093\/rheumatology\/ket170 .","journal-title":"Rheumatology (Oxford)"},{"key":"1170_CR30","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1002\/art.34343","volume":"64","author":"CA Wallace","year":"2012","unstructured":"Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O\u2019Neil KM, Zeft AS, et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum. 2012;64:2012\u201321. doi: 10.1002\/art.34343 .","journal-title":"Arthritis Rheum"},{"key":"1170_CR31","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1136\/ard.2010.143347","volume":"70","author":"P Tynj\u00e4l\u00e4","year":"2011","unstructured":"Tynj\u00e4l\u00e4 P, V\u00e4h\u00e4salo P, Tarkiainen M, Kr\u00f6ger L, Aalto K, Malin M, et al. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. Ann Rheum Dis. 2011;70:1605\u201312. doi: 10.1136\/ard.2010.143347 .","journal-title":"Ann Rheum Dis"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-016-1170-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T20:54:58Z","timestamp":1749761698000},"score":1,"resource":{"primary":{"URL":"http:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-016-1170-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,24]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1170"],"URL":"https:\/\/doi.org\/10.1186\/s13075-016-1170-3","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,24]]},"article-number":"272"}}